Announcement of Availability for IMC-F106C
July 31, 2024
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using IMC-F106C, a T-cell receptor (TCR)/anti-CD3 fusion protein that targets tumor cell surface peptides in complex with human leukocyte antigen (HLA). IMC-F106C is being developed by CTEP as an anticancer agent in collaboration with Immunocore. CTEP will also consider requests to supply IMC-F106C for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and when appropriate, robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).
All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
If you are a DFHCC Investigator interested in submitting an LOI using IMC-F106C through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)
Questions may be addressed to Dr. Howard Streicher (streicherh@ctep.nci.nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
For more information please see the Related Links Below: